1. Home
  2. RXT vs XERS Comparison

RXT vs XERS Comparison

Compare RXT & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RXT
  • XERS
  • Stock Information
  • Founded
  • RXT 1998
  • XERS 2005
  • Country
  • RXT United States
  • XERS United States
  • Employees
  • RXT N/A
  • XERS N/A
  • Industry
  • RXT EDP Services
  • XERS Biotechnology: Pharmaceutical Preparations
  • Sector
  • RXT Technology
  • XERS Health Care
  • Exchange
  • RXT Nasdaq
  • XERS Nasdaq
  • Market Cap
  • RXT 524.5M
  • XERS 500.2M
  • IPO Year
  • RXT 2020
  • XERS 2018
  • Fundamental
  • Price
  • RXT $2.45
  • XERS $3.34
  • Analyst Decision
  • RXT Hold
  • XERS Buy
  • Analyst Count
  • RXT 6
  • XERS 3
  • Target Price
  • RXT $2.47
  • XERS $4.87
  • AVG Volume (30 Days)
  • RXT 761.3K
  • XERS 1.3M
  • Earning Date
  • RXT 03-11-2025
  • XERS 03-05-2025
  • Dividend Yield
  • RXT N/A
  • XERS N/A
  • EPS Growth
  • RXT N/A
  • XERS N/A
  • EPS
  • RXT N/A
  • XERS N/A
  • Revenue
  • RXT $2,771,200,000.00
  • XERS $187,361,000.00
  • Revenue This Year
  • RXT N/A
  • XERS $24.27
  • Revenue Next Year
  • RXT N/A
  • XERS $18.57
  • P/E Ratio
  • RXT N/A
  • XERS N/A
  • Revenue Growth
  • RXT N/A
  • XERS 22.72
  • 52 Week Low
  • RXT $1.45
  • XERS $1.69
  • 52 Week High
  • RXT $3.41
  • XERS $3.87
  • Technical
  • Relative Strength Index (RSI)
  • RXT 53.77
  • XERS 49.66
  • Support Level
  • RXT $2.31
  • XERS $3.14
  • Resistance Level
  • RXT $2.53
  • XERS $3.60
  • Average True Range (ATR)
  • RXT 0.16
  • XERS 0.17
  • MACD
  • RXT 0.03
  • XERS -0.02
  • Stochastic Oscillator
  • RXT 61.82
  • XERS 37.74

About RXT Rackspace Technology Inc.

Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Share on Social Networks: